Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - Gilead is focusing on its growth story for 2026 and beyond, emphasizing the importance of its recent developments and pipeline [2][3] - The launch of lenacapavir in 2025 was a significant milestone for Gilead, highlighting its commitment to addressing the global HIV epidemic [3] - Gilead's commercial growth has been robust, with a strong and diverse pipeline, marking a significant period of launch activity [4] Company Highlights - Gilead's pipeline is described as the strongest and most diverse in its nearly 40-year history, indicating a promising future for the company [4] - The company distinguishes itself from other big pharma firms by not facing any major loss of exclusivity (LOE) issues, which positions it favorably in the market [4]